Search results
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 2 days agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 7 hours agoIII Multiple Myeloma Study on BCMA Therapy, ABBV-383: AbbVie announced that it has initiated a phase...
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
KOLR - KSFX Ozarks· 6 days agoImmunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully ...
InDevR and Sino Biological Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and...
Digital Journal· 2 days agoThrough this partnership, Sino Biological's catalog of high-quality antibodies, antigens, and other reagents are available for use on InDevR's VaxArray Platform . Biopharmaceutical ...
Artificial lymph nodes teaches T cells to kill cancer
Futurity· 3 hours agoScientists have developed an artificial lymph node with the potential to treat cancer, according to...
New Jersey Hospitals Offer State-of-the-Art Technologies
New Jersey Business Magazine· 2 hours agoNew Jersey hospitals incorporate state-of-the-art technologies into their daily treatments and...
...Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with...
KOIN News 6 Portland· 5 days ago...that develops, manufactures and commercializes high-quality medicines for the treatment of...
... Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of...
KOIN News 6 Portland· 5 days ago...biopharmaceutical company that develops, manufactures and commercializes high-quality medicines...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoAn additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses
The chicken and egg problem of fighting another flu pandemic
Salon via Yahoo News· 6 days agoIt’s not so funny, he said, when the currently stockpiled formulation against the H5N1 bird flu...